Fig. 2

The time change of various clinical characteristics in the VR and NVR group. ALT (A), AST (B), HBsAg (C), HBV-DNA (D), Tbil (E), and WBC (F) levels in VR and NVR patients received 48-week Peg-IFN-α treatment; *P < 0.05, **P < 0.01; ●, represents the median value of each parameter in the group with virological response; ■, represents the median value of each parameter in the group without virological response; the bottom and top of the whiskers represent 25 and 75 percentiles of each parameter